Loading
A phase 1 trial of DMR-001 run by Damora Therapeutics, now recruiting.
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms is a phase 1 interventional study registered as NCT07849231 by Damora Therapeutics, with 250 participants planned, started 2026-09. Conditions recorded: Myeloproliferative Neoplasms (MPNs). Interventions recorded: DMR-001 and Ruxolitinib.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/